Navigation Links
New type of rejection blocker protects kidneys after transplant

UCSF enrolled the first patient to receive belatacept in the trial early in 2001. Twenty UCSF patients have been taking the drug for more than three years. "So far, results are excellent for long-term recipients of the treatment," Vincenti said.

A UCSF immunologist whose research has led to the development of immune tolerance drugs, Jeffrey Bluestone, PhD, put the study in context. "This work underscores the enormous potential of co-stimulatory blockade as a strategy for inducing immune tolerance, not only in transplantation, but in autoimmune diseases as well," Bluestone said. He is UCSF professor of medicine and director of the Immune Tolerance Network (ITN), an NIH-funded international network of more than 80 researchers coordinating clinical testing of new therapies to induce immune tolerance.

"Additionally, this phase II study provides a solid foundation for Dr. Vincenti's upcoming ITN-sponsored study of belatacept in kidney transplant recipients, in which we will test whether true immune tolerance can be achieved," Bluestone said. That new trial, to begin this fall enrolling patients who receive kidney transplants from living donors at UCSF, will test whether transplant patients can be treated with belatacept and can gradually withdraw from all immunosuppressants -- including belatacept itself.

In addition, Bristol-Myers Squibb Company, the pharmaceutical company that developed belatacept, is conducting phase III clinical trials of the drug for kidney transplants. UCSF also is participating in that trial.

RESEARCH RESULTS

Belatacept is an injectable protein, one of a group of experimental drugs called co-stimulatory blockers. The immune system's normal response to a transplant is to recognize the new organ as foreign and to signal production of T-cells poised to destroy it. A second, co-stimulatory signal is required before the T-cells attack the kidney. By blocking this second signal, belatacept prevents de
'"/>

Source:University of California - San Francisco


Page: 1 2 3 4

Related biology news :

1. Simple sea sponge helps scientists understand tissue rejection
2. Researchers identify genes associated with lung transplant rejection
3. Carnegie Mellon develops non-invasive technique to detect transplant rejection at cellular level
4. Combination therapy with a monocloncal antibody and a vaccine leads to tumor rejection
5. Proteins may predict lung transplant rejection
6. Survival of heart patients on beta-blockers varies greatly with genetic variation
7. Bound for destruction: Ubiquitination protects against improper Notch signaling
8. Experiments provide proof of how traveling in groups protects insects
9. Experiments provide proof of how traveling in groups protects insects
10. Substance protects resilient staph bacteria
11. Molecule that usually protects infection-fighting cells may cause plaque deposits inside arteries
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New type rejection blocker protects kidneys after transplant

(Date:4/14/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces that its ... New York Design Awards under the category  ,Product Design ... Design Awards are part of a global multi-disciplinary awards ... from the marketplace, industry and judging panel. Winners will ...
(Date:4/9/2015)... , April 9, 2015 Synaptics Inc. (NASDAQ: ... announced today that it will report financial results for ... 23, 2015, after the close of market. The company ... investors at 2:00 p.m. PT (5:00 p.m. ET), during ... To participate on the live call, analysts and investors ...
(Date:4/2/2015)... Md. , April 2, 2015 At ... Salt Lake City , the American College ... of five new directors to its Board.  Members of ... the ACMG and for forming and advancing its policies ... medical genetics profession. "It,s an eventful time ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3Synaptics to Report Third Quarter Results on April 23 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8
... LEDs may help reduce skin ... in Germany are describing a potential alternative to Botox ... scheduled for the November 5 issue of ACS, ... that high intensity visible light from light emitting diodes ...
... cleavage product, amyloid-b (Ab), builds up into fibrous plaques ... one specialized membrane microdomain to another to be cleaved, ... definitive evidence that Ab plaques are the direct cause ... support this. And working on this hypothesis, scientists are ...
... one step closer to finding a vaccine that better ... at Saint Louis University appears likely to offer significantly ... one in current use. "Not only was it ... better immune response, which suggests it will be more ...
Cached Biology News:American Chemical Society Weekly PressPac Oct. 15, 2008 2American Chemical Society Weekly PressPac Oct. 15, 2008 3American Chemical Society Weekly PressPac Oct. 15, 2008 4American Chemical Society Weekly PressPac Oct. 15, 2008 5American Chemical Society Weekly PressPac Oct. 15, 2008 6American Chemical Society Weekly PressPac Oct. 15, 2008 7American Chemical Society Weekly PressPac Oct. 15, 2008 8Research identifies type of vaccine that holds promise in protecting against TB 2
(Date:4/27/2015)... 27, 2015 SynGen Inc., a company that ... that harvest stem and progenitor cells from umbilical cord ... today that it has added three new members to ... Blood Business Units focus on product commercialization. ... its Vice President and Chief Financial Officer.  Chuck was ...
(Date:4/27/2015)... tru Shrimp™ Systems announced today that it has ... the exclusive worldwide rights to commercialize Tidal Basin™ technology, ... agreement for the patented technology, developed by world-renowned shrimp ... China, Taiwan, France, Germany, Italy, Spain, the Netherlands and ... from all over the world for our Tidal Basin™ ...
(Date:4/24/2015)... April 24, 2015 Top student social ... San Diego area universities, including UCSD and SDSU, will ... from prominent local, national and nonprofit companies for an ... 5th Annual Social Innovation Challenge 2015 . , ... social venture ideas addressing a diverse range of issues ...
(Date:4/24/2015)... DIEGO , April 24, 2015  Pfenex Inc. ... the development of biosimilar therapeutics including high value and ... its follow-on public offering of 6,000,000 shares of its ... $15.50 per share. Of the shares being offered, 2,610,000 ... shares are being offered by existing stockholders. Pfenex will ...
Breaking Biology Technology:SynGen Inc. Expands Its Management Team 2tru Shrimp™ Systems Acquires Global Patent for Tidal Basin™ Shrimp Production 25th Annual Social Innovation Challenge at University of San Diego - Students Pitch to Live Judging Panel to Take Home $75K 25th Annual Social Innovation Challenge at University of San Diego - Students Pitch to Live Judging Panel to Take Home $75K 3Pfenex Inc. Announces Pricing Of Follow-on Offering 2
... LA JOLLA, Calif., March 18 TorreyPines Therapeutics,Inc. ... initiated a Phase II study of,NGX267, a muscarinic ... to Sjogren,s syndrome., The company is conducting ... square design to evaluate,the safety, tolerability and efficacy ...
... NEOG ) announces the following Webcast:, What: Neogen ... EDT, Where: http://www.videonewswire.com/event.asp?id=46587 , How: ... the address above., ... are unable to participate during the live webcast, the call will,be archived ...
... - Oncolytics Biotech Inc.,(TSX: ONC, NASDAQ: ONCY) ("Oncolytics") ... 7,344,711 entitled "Use of Adenoviruses Mutated in the,VA ... of treating,cancer using adenoviruses that are modified to ... Ras pathway., "This patent expands our adenovirus ...
Cached Biology Technology:TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 2TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 3TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 4Oncolytics Biotech Inc. Announces Issuance of 26th U.S. Patent 2
... on over 20 years of experience in ... Life Sciences, the Freedom EVO platform delivers ... according to future needs. Together with the ... is equipped to successfully operate genomics, proteomics, ...
... Use in any standard fixed-angle ... 16,000 g.,Spin- centrifuge tube filters ... within a centrifuge tube. They filter ... removal, HPLC sample preparation, removal of ...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. Material: polystyrene ...
12 breakable polypropylene strips of 8 wells each held in a rigid frame. Ideal for antibody assays....
Biology Products: